Art. -Nr.: HY-N0087

Gambogic Acid

(Synonyms: Beta-Guttiferrin)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-X_L, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC₅₀s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.34%
CAS. Nr.: 2752-65-0
Formel: C₃₈H₄₄O₈
Molecular Weight:628.75

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Gambogic Acid Chemical Structure

CAS. Nr.: 2752-65-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Bcl-B

0.66 μM (IC₅₀)

Mcl-1

0.79 μM (IC₅₀)

Bfl-1

1.06 μM (IC₅₀)

Bcl-2

1.21 μM (IC₅₀)

Bcl-xL

1.47 μM (IC₅₀)

Bcl-W

2.02 μM (IC₅₀)

Autophagy

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.81 μM Compound: gambogic acid, GA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 18996626]
A549	IC₅₀	3.65 μM Compound: GA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20605273]
A549	IC₅₀	1.1 μM Compound: GA	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 22472167]
A549	IC₅₀	0.5 μg/mL Compound: GA	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22595179]
A549	IC₅₀	1.1 μM Compound: 1, GA	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 23167526]
A549	IC₅₀	1.1 μM Compound: GA	Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 25958244]
A549	IC₅₀	3.4 μM Compound: 4	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 to 48 hrs by Presto Blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 to 48 hrs by Presto Blue assay	[PMID: 27216998]
A549	IC₅₀	1.2 μM Compound: 1; GA	Antiproliferative activity against human A549 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
A549	IC₅₀	1.47 μM Compound: GA	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31047774]
A549	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
A549/CDDP	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human A549/CDDP cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549/CDDP cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
A549/TR	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
Bel-7402	IC₅₀	3.31 μM Compound: gambogic acid, GA	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 18996626]
Bel-7402	IC₅₀	2.08 μM Compound: GA	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 20605273]
Bel-7402	IC₅₀	0.75 μM Compound: 1, GA	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 22153338]
BEL-7404 tumor cell line	IC₅₀	4.7 μM Compound: 1, GA	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 22153338]
BGC-823	IC₅₀	4.51 μM Compound: gambogic acid, GA	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 18996626]
BGC-823	IC₅₀	2.83 μM Compound: GA	Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay	[PMID: 20605273]
BGC-823	IC₅₀	2.35 μM Compound: 1, GA	Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay	[PMID: 21334116]
BJ	EC₅₀	0.21 μM Compound: Gambogic acid	Cytotoxicity against human BJ cells Cytotoxicity against human BJ cells	[PMID: 25316317]
Breast carcinoma cell	IC₅₀	0.42 μM Compound: GBA; 1	Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay	[PMID: 30831408]
DU-145	IC₅₀	0.3 μg/mL Compound: GA	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 22595179]
HCT-116	EC₅₀	0.7 μM Compound: 1, GA	Induction of apoptosis in human HCT116 cells assessed as caspase 3 activation after 24 hrs Induction of apoptosis in human HCT116 cells assessed as caspase 3 activation after 24 hrs	[PMID: 18337106]
HCT-116	GI₅₀	0.1 μM Compound: 1, GA	Growth inhibition of human HCT116 cells after 48 hrs by CellTiter-Glo assay Growth inhibition of human HCT116 cells after 48 hrs by CellTiter-Glo assay	[PMID: 18337106]
HCT-116	IC₅₀	3.11 μM Compound: GA	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31047774]
HCT-116	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
HEK293	EC₅₀	0.21 μM Compound: Gambogic acid	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 25316317]
HEK293	IC₅₀	1.72 μM Compound: 4	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 24 to 48 hrs by trypan blue dye based fluorescence assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 24 to 48 hrs by trypan blue dye based fluorescence assay	[PMID: 27216998]
HeLa	IC₅₀	0.7 μM Compound: 6a, R-gambogic acid	Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay	[PMID: 19072548]
HeLa	GI₅₀	1.5 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay	[PMID: 21486005]
HepG2	IC₅₀	2.4 μM Compound: GA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20338759]
HepG2	IC₅₀	2.4 μM Compound: 1, GA	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 21334116]
HepG2	IC₅₀	1.17 μM Compound: 1, GA	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22153338]
HepG2	IC₅₀	0.89 μM Compound: 1, GA	Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 23167526]
HepG2	EC₅₀	<2 μM Compound: Gambogic acid	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 25316317]
HepG2	IC₅₀	0.89 μM Compound: GA	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 25958244]
HepG2	IC₅₀	2.19 μM Compound: 1; GA	Antiproliferative activity against human HepG2 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
HepG2	IC₅₀	1.55 μM Compound: Gambogic acid	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 30594028]
HepG2	IC₅₀	2.36 μM Compound: GA	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31047774]
HepG2	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
HL-60	GI₅₀	0.3 μM Compound: Gambogic acid	Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay	[PMID: 29565129]
HL-60	IC₅₀	0.17 μM Compound: 54	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by trypan blue dye based hemocytometer counting method Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 3 days by trypan blue dye based hemocytometer counting method	[PMID: 30830783]
HT-29	IC₅₀	5.61 μM Compound: gambogic acid, GA	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 18996626]
HT-29	IC₅₀	3.52 μM Compound: GA	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20605273]
HT-29	ED₅₀	0.48 μM Compound: 1	Anticancer activity aganist human HT-29 cells Anticancer activity aganist human HT-29 cells	[PMID: 21067206]
HT-29	IC₅₀	2.37 μM Compound: 1; GA	Antiproliferative activity against human HT-29 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
K562	GI₅₀	0.6 μM Compound: Gambogic acid	Growth inhibition of human K562 cells measured after 3 days by trypan blue assay Growth inhibition of human K562 cells measured after 3 days by trypan blue assay	[PMID: 29565129]
K562	IC₅₀	0.62 μM Compound: Gambogic acid	Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 48 to 72 hrs by MTS assay Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 48 to 72 hrs by MTS assay	[PMID: 35551036]
KB	IC₅₀	0.3 μg/mL Compound: GA	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 22595179]
MCF7	IC₅₀	0.5 μM Compound: GA	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20338759]
MCF7	IC₅₀	2.19 μM Compound: 1, GA	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21334116]
MCF7	GI₅₀	2 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay	[PMID: 21486005]
MCF7	IC₅₀	1.25 μM Compound: 1; GA	Antiproliferative activity against human MCF7 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
MDA-MB-231	IC₅₀	1.33 μM Compound: GA	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 31047774]
MKN-45	IC₅₀	4.27 μM Compound: GA	Antiproliferative activity against human MKN45 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells incubated for 72 hrs by MTT assay	[PMID: 31047774]
PC-3	IC₅₀	1.19 μM Compound: 1; GA	Antiproliferative activity against human PC3 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human PC3 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
Raji	EC₅₀	0.24 μM Compound: Gambogic acid	Cytotoxicity against human Raji cells Cytotoxicity against human Raji cells	[PMID: 25316317]
SGC-7901	IC₅₀	1.47 μM Compound: GA	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 20338759]
SK-BR-3	GI₅₀	0.8 μM Compound: 1	Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay Antiproliferative activity against human SKBR3 cells assessed as inhibition of cell growth after 72 hrs by cell titer 96 assay	[PMID: 21486005]
SK-BR-3	IC₅₀	0.89 μM Compound: 1; GA	Antiproliferative activity against human SK-BR-3 cells assessed as growth inhibition by MTT assay Antiproliferative activity against human SK-BR-3 cells assessed as growth inhibition by MTT assay	[PMID: 27527413]
SK-OV-3	IC₅₀	3.06 μM Compound: gambogic acid, GA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 18996626]
SMMC-7721	IC₅₀	3.2 μM Compound: 1, GA	Antiproliferative activity against human SMMC7721 cells after 24 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 24 hrs by MTT assay	[PMID: 21334116]
SMMC-7721	IC₅₀	1.13 μM Compound: 1, GA	Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 22153338]
SNU-398	EC₅₀	0.7 μM Compound: 1, GA	Induction of apoptosis in human SNU398 cells assessed as caspase 3 activation after 24 hrs Induction of apoptosis in human SNU398 cells assessed as caspase 3 activation after 24 hrs	[PMID: 18337106]
SNU-398	GI₅₀	0.2 μM Compound: 1, GA	Growth inhibition of human SNU398 cells after 48 hrs by CellTiter-Glo assay Growth inhibition of human SNU398 cells after 48 hrs by CellTiter-Glo assay	[PMID: 18337106]
T47D	EC₅₀	0.7 μM Compound: 1, GA	Induction of apoptosis in human T47D cells assessed as caspase 3 activation after 24 hrs Induction of apoptosis in human T47D cells assessed as caspase 3 activation after 24 hrs	[PMID: 18337106]
T47D	GI₅₀	0.2 μM Compound: 1, GA	Growth inhibition of human T47D cells after 48 hrs by CellTiter-Glo assay Growth inhibition of human T47D cells after 48 hrs by CellTiter-Glo assay	[PMID: 18337106]
T98G	IC₅₀	≤300 nM Compound: GA	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
U-251	IC₅₀	2.56 μM Compound: GA	Antiproliferative activity against human U251 cells after 24 hrs by MTT assay Antiproliferative activity against human U251 cells after 24 hrs by MTT assay	[PMID: 22472167]
U-251	IC₅₀	2.56 μM Compound: 1, GA	Cytotoxicity against human U251 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human U251 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 23167526]
U-251	IC₅₀	2.56 μM Compound: GA	Cytotoxicity against human U251 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human U251 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 25958244]
U-251	IC₅₀	0.29 μM Compound: Gambogic acid	Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]

In Vitro

Gambogic Acid (Beta-Guttiferrin) is a medicinal compound derived from the gamboges resin of the tree, Garcinia hanburyi. Gambogic Acid has documented cytotoxic activity against tumor cell lines in culture, with concentrations required for killing 50% of cells (LD₅₀ of ~1 μM). The activity of Gambogic Acid against the 6 human anti-apoptotic Bcl-2-family proteins is contrasted, using FPAs. Gambogic Acid displaces to various extents FITC-BH3 peptide binding to all 6 proteins, with apparent IC₅₀ 1.47 μM for Bcl-X_L, 1.21 μM for Bcl-2, 2.02 μM for Bcl-W, 0.66 μM for Bcl-B, 1.06 μM for Bfl-1, and 0.79 μM for Mcl-1^[1]. The growth inhibitory effects of Gambogic Acid or Cisplatin (CDDP) on A549, NCI-H460, and NCI-H1299 cells are assessed by the MTT assay after 48?h exposure. A concentration-dependent inhibition of cell growth is observed with Gambogic Acid and CDDP, with IC₅₀s of 3.56±0.36 and 21.88±3.21?μM for A549 cells, 4.05±0.51 and 25.76±4.03?μM for NCI-H460 cells, and 1.12±0.31?μM and 25.21±4.38?μM for NCI-H1299 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To further investigate whether Gambogic Acid (Beta-Guttiferrin) synergises CDDP against tumour growth in vivo, A549 tumors are implanted in SCID mice. When mice are treated with CDDP combined with Gambogic Acid, the tumor inhibition rate is 69.3%, whereas those of mice treated with CDDP and GA alone are 57.2% and 29.0%, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2752-65-0
Appearance Solid
Molecular Weight 628.75
Formel C₃₈H₄₄O₈
Color Yellow to orange
SMILES

O=C(O)/C(C)=C\C[C@@]1(C2=O)OC(C)(C)[C@@](C[C@@]2([H])C=C34)([H])[C@]31OC5=C(C(O)=C(C=C[C@](CC/C=C(C)/C)(C)O6)C6=C5C/C=C(C)\C)C4=O
Synonyms

Beta-Guttiferrin
Structure Classification
- Others
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayIn Vivo Efficacy StudyFlow Cytometry

Sort by:

Journal Impact Factor

Redox Biol

TrxR1 is involved in the activation of Caspase-11 by regulating the oxidative-reductive status of Trx-1. [Abstract]

2024 Sep:75:103277. PMID: 39059206

Gambogic Acid purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep:75:103277. [Abstract]

Analysis of LDH release in E. coli-infected J774A.1 cells treated with GA (Gambogic Acid, 0.5-1 μM). n = 3 per group.
Chem Eng J

2026 Jan 24;530:173330.
Sci Rep

BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. [Abstract]

2022 Mar 8;12(1):4038. PMID: 35260587

Gambogic Acid purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Mar 8;12(1):4038. [Abstract]

Viability of TNBC cell line MDA-MB-231 with Gambogic acid, an antagonist of antiapoptotic Bcl-2 family. Bar graph represents MDA-MB-231 MTT cell viability assay after treatment with Gambogic acid (0.06-1 μM) in the combination of with/without CAP treatment at 80p 5 min at 3 L/min He.
Cell Signal

Gambogic acid induces ferroptosis and suppresses colorectal cancer progression by modulating the m6A modification of p62. [Abstract]

2025 Nov:135:112024. PMID: 40721064

Gambogic Acid purchased from MedChemExpress. Usage Cited in: Cell Signal. 2025 Nov:135:112024. [Abstract]

Intracellular Fe²⁺ levels were measured using the iron ion assay kit in HCT116 after treatment with GA (Gambogic Acid; 0.5-1 μM; 24 h) at different concentrations (HCT116: 0 μM, 0.5 μM, 1 μM; HT29: 0 μM, 0.75 μM, 1.5 μM).
Cell Adh Migr

Fe3O4 nanoparticles containing gambogic acid inhibit metastasis in colorectal cancer via the RORB/EMILIN1 axis. [Abstract]

2024 Dec;18(1):38-53. PMID: 39533963
Drug Dev Res

Mechanism of gambogic acid repressing invasion and metastasis of colorectal cancer by regulating macrophage polarization via tumor cell-derived extracellular vesicle-shuttled miR-21. [Abstract]

2024 Feb;85(1):e22141. PMID: 38349264

Gambogic Acid purchased from MedChemExpress. Usage Cited in: Drug Dev Res. 2024 Feb;85(1):e22141. [Abstract]

Liver morphology and nodule status in nude mice 4 weeks after intraperitoneal injection of HT-29 cells and GA (Gambogic Acid; 20 mg/kg) treatment. It was observed that compared to the PC + DMSO group, the PC + GA group had fewer liver metastatic nodules.

Gambogic Acid purchased from MedChemExpress. Usage Cited in: Drug Dev Res. 2024 Feb;85(1):e22141. [Abstract]

The percentages of CD68 + CD86 cells and CD68 + CD206 cells were measured by flow cytometry, N = 6. The results displayed that relative to the PC + DMSO group, the levels of CD68+CD86 cells in the PC + GA (Gambogic Acid; 20 mg/kg; i.p.; 4 weeks) group obviously rised, while the levels of CD68+CD206 cells were prominently reduced (all p < .001).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (79.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5905 mL

7.9523 mL

15.9046 mL

5 mM

0.3181 mL

1.5905 mL

3.1809 mL

10 mM

0.1590 mL

0.7952 mL

1.5905 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

The in vitro cell viability effects of Gambogic Acid, CDDP alone, or combined treatments are determined by MTT assay. The cells (2×10⁴ cells per mL) are seeded into 96-well culture plates. After overnight incubation, A549 cells are treated with Gambogic Acid (0.44, 0.88, 1.75, 3.5, 7, 10.5 and 14 μM); NCI-H460 cells are treated with Gambogic Acid (0.5, 1, 2, 4, 8, 12 and 16 μM); NCI-H1299 cells are treated with Gambogic Acid (0.125, 0.25, 0.5, 1, 2 and 4 μM). For the combined treatment in NSCLC cells, three sequences are tested: (a) Gambogic Acid followed by CDDP cells are exposed to Gambogic Acid for 48 h, and then after washout of Gambogic Acid, cells are treated with CDDP for an additional 48 h; (b) CDDP followed by Gambogic Acid cells are exposed to CDDP for 48 h, and then after washout of CDDP, cells are treated with Gambogic Acid for an additional 48 h; and (c) concurrent treatment cells are exposed to both Gambogic Acid and ADM for 48 h. The nature of the drug interaction is analysed by using the combination index (CI)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
To determine the in vivo antitumour activity of Gambogic Acid combined with CDDP, viable A549 cells (5×10⁶/100 μL PBS per mouse) are subcutaneously injected into the right flank of 7- to 8-week-old male SCID mice. When the average tumor volume reach 100 mm³, the mice are randomly divided into four treatment groups, including control (saline only, n=5), Gambogic Acid (3.0 mg/kg per 2 days, intravenously; n=6), CDDP (4 mg/kg per week, intravenously; n=6), and sequential combination (CDDP treatment one day before Gambogic Acid treatment, n=6). CDDP (4 mg/kg, weekly) is generally administered at doses less than the maximum-tolerated dose in an attempt to allow any additive effects of combination treatment with platinum-based agents and Gambogic Acid to be more easily detected. Tumor size is measured once every 2 days with a calipre. Body weight is recorded once every 2 days. After 14 days, the mice are killed and the tumors are excised and stored at -80 °C until further analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhai D, et al. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008 Jun;7(6):1639-46. [Content Brief]

[2]. Wang LH, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling. Br J Cancer. 2014 Jan 21;110(2):341-52. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5905 mL	7.9523 mL	15.9046 mL	39.7614 mL
	5 mM	0.3181 mL	1.5905 mL	3.1809 mL	7.9523 mL
	10 mM	0.1590 mL	0.7952 mL	1.5905 mL	3.9761 mL
	15 mM	0.1060 mL	0.5302 mL	1.0603 mL	2.6508 mL
	20 mM	0.0795 mL	0.3976 mL	0.7952 mL	1.9881 mL
	25 mM	0.0636 mL	0.3181 mL	0.6362 mL	1.5905 mL
	30 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3254 mL
	40 mM	0.0398 mL	0.1988 mL	0.3976 mL	0.9940 mL
	50 mM	0.0318 mL	0.1590 mL	0.3181 mL	0.7952 mL
	60 mM	0.0265 mL	0.1325 mL	0.2651 mL	0.6627 mL

Keywords

Gambogic Acid

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Gambogic Acid

Traditional Chinese Medicine Active Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Food-Sourced Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Publications Citing Use of MedChemExpress (MCE) Gambogic Acid

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Gambogic Acid

Traditional Chinese Medicine Active Compound Library

Anti-Blood Cancer Compound Library

Mitochondria-Targeted Compound Library

Food-Sourced Compound Library

Targeted Diversity Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Publications Citing Use of MedChemExpress (MCE) Gambogic Acid

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Gambogic Acid Related Classifications

HY-N0087 Related Classifications